CN109091682A - 99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer - Google Patents
99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer Download PDFInfo
- Publication number
- CN109091682A CN109091682A CN201710470269.XA CN201710470269A CN109091682A CN 109091682 A CN109091682 A CN 109091682A CN 201710470269 A CN201710470269 A CN 201710470269A CN 109091682 A CN109091682 A CN 109091682A
- Authority
- CN
- China
- Prior art keywords
- rgd2
- ratio
- choroid
- mela
- noma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
Abstract
The invention discloses99mThe new application of Tc-3P-RGD2 is after protecting eyeball treatment using prediction with ultrasonic in combination that mela-noma of choroid shifts, and principle is the quantity of mela-noma of choroid new vessels in unit of account volume.Intravenous injection99mRow SPECT-CT is imaged after Tc-3P-RGD2,99mTc-3P-RGD2 can concentrate in tumor locus, calculate tumour and occipital bone region of interest ratio (T/O) according to image；Ultrasonoscopy measures tumour longest edge and most broadside, calculates gross tumor volume, is defined as V；(T/O)/V ratio is calculated, if (T/O)/V ratio is greater than 0.005, then it is assumed that shift risk larger；If if (T/O)/V ratio is between 0 to 0.005, then it is assumed that shift risk not higher than average level.
Description
It is related to field
The present invention relates to field of medicaments, are characterized in particular in a kind of nucleus medical imaging agent99mTc-3P-RGD2 is pernicious in prediction eye
The application of tumour mela-noma of choroid transfer aspect, this is to use with ultrasonic in combination using implementation method.
Background technique
Mela-noma of choroid (choroidal melanoma) is the primary malignant tumor for betiding human choroidal,
Currently used treatment method includes protecting eyeball treatment and extracing eyeball treatment, the former is such as laser therapy, radioactive particle application
Treatment etc..The selection of therapeutic scheme depends on funduscopy and morphological examination (including CT examination, eye B ultrasound, magnetic resonance
MRI etc.).Clinically more general method is that the U.S. cooperates with ophthalmo melanoma Guide to research (Collaborative Ocular
Melanoma Study, COMS) provide reference frame: to tumour substrate be greater than 16mm or height be greater than 10mm patient's row eye
Ball is extractd.Eyeball treatment is protected to patient's row that substrate and height are less than this numerical value.Some researches show that mela-nomas of choroid to grow
Rate rather than gross tumor volume itself and tumour early stage transfer and fractionated radiation treatments failure are related, for using laser, application etc.
The No operation of therapeutic modality extracts eyeball patient, potentially shifts risk since it will undertake, except commenting tumor morphology
Outside valence, the risk of tumor proliferation, invasion should also be evaluated.Tumor proliferation, invasion need new vessels to be provided nutrition
With oxygen, integrin is distributed across one of molecular marked compound of endothelial cells in tumor neogenetic blood vessels, therefore the expression quantity of integrin
Tumor neovasculature quantity can be characterized, metastases ability is further measured.The integrin imaging of isotope labeling has been answered
For lung cancer, breast cancer etc., the research for mela-noma of choroid is less.
99mTc-3P-RGD2 is a kind of integrin imaging medicament of isotope labeling, synthesis mode such as patent CN
102552949 A are announced.
The invention discloses99mThe new application of Tc-3P-RGD2 is to protect arteries and veins after eyeball is treated using prediction with ultrasonic in combination
Network film melanoma metastasis, principle are the quantity of mela-noma of choroid new vessels in unit of account volume.It is so far
Only,99mApplication of the Tc-3P-RGD2 for mela-noma of choroid imaging has not been reported, and uses with ultrasonic in combination and also has not been reported.
Summary of the invention
The object of the present invention is to provide99mThe new application of Tc-3P-RGD2.
It is provided by the present invention99mThe new application of Tc-3P-RGD2 is: using with ultrasonic in combination, is used in prediction eye and dislikes
Property tumour mela-noma of choroid transfer aspect application.
Purposes of the present invention needs to be injected intravenously99mRow SPECT-CT is imaged after Tc-3P-RGD2,99mTc-3P-RGD2
Tumor locus can be concentrated in, makes imaging that the color for being deeper than background be presented, needs to calculate tumour and occipital bone region of interest according to image
Ratio (T/O), tumour region of interest delineate mode are as follows: delineate the edge for being deeper than the color of background, the hook of occipital bone region of interest
Picture mode are as follows: 16 pixel pictures are delineated at occipital bone image.SPECT-CT processing system can give region of interest mean intensity number
Value.The higher expression tissue pair of mean intensity99mTc-3P-RGD2 intake is higher.Purposes of the present invention needs ultrasound to need simultaneously
Measure tumour height and substrate numerical value.Ultrasonoscopy measures tumour longest edge and most broadside, calculates gross tumor volume, is defined as V；
(T/O)/V ratio is calculated, if (T/O)/V ratio is greater than 0.005, then it is assumed that shift risk larger；If if (T/O)/V ratio
Value is between 0 to 0.005, then it is assumed that shifts risk not higher than average level.
It is provided by the present invention99mThe new application dosage of Tc-3P-RGD2 imaging is 0.3mCi/Kg weight (people).
Objects and advantages of the present invention will be illustrated and explained by the non-limitative illustration of following preferred embodiments, this
A little embodiments provide as an example referring to attached drawing.
Detailed description of the invention
Fig. 199mTc-3P-RGD2 imaging is used for mela-noma of choroid with ultrasonoscopy.Left figure: choroid melanin
Tumor99mTc-3P-RGD2 imaging；Right figure: mela-noma of choroid ultrasonoscopy, from two angle measurement tumour substrate and height
Numerical value: it is respectively substrate 15.1mm, height 9.2mm, is all satisfied eyeball therapeutic modality condition of protecting, therefore patient's selective emission grain
Sub- application therapy condition.The present embodiment T/O/V value is 0.0023, less than 0.005.Follow-up is good to 20 months Partial controlls.
Fig. 299mTc-3P-RGD2 imaging is used for mela-noma of choroid with ultrasonoscopy.Left figure: choroid melanin
Tumor99mTc-3P-RGD2 imaging；Right figure: mela-noma of choroid ultrasonoscopy, from two angle measurement tumour substrate and height
Numerical value: it is respectively substrate 9.5mm, height 3.2mm, is all satisfied eyeball therapeutic modality condition of protecting, therefore patient's selective emission grain
Sub- application therapy condition.The present embodiment T/O/V value is 0.0089, is greater than 0.005.Radioactive particle application therapy is sent out after 6 months
Existing hepatic metastases.
Fig. 399mRelationship between the T/O ratio and ultrasonoscopy cubing of Tc-3P-RGD2 imaging.
Specific embodiment
Embodiment 1:99mTc-3P-RGD2 imaging is used for mela-noma of choroid with ultrasonoscopy,
Patients surgery treat move ahead ultrasonoscopy with99mTc-3P-RGD2 imaging.
Ultrasonoscopy: eye ultrasonoscopy measures mela-noma of choroid base length and tumour height, according to following public affairs
Formula calculates volume: V=2 л a2B/3 (v: volume；A: tumour base length/2；B: height), according to this example substrate 15.1mm, height
9.2mm, volume 1097.7mm3
99mTc-3P-RGD2 imaging: will99mTc-3P-RGD2 is injected intravenously according to 3mCi/Kg weight into patient's body, and 1 is small
When after SPECT image, delineate region of interest, tumour region of interest delineates mode are as follows: delineates the side for being deeper than the color of background
Edge, occipital bone region of interest delineate mode are as follows: 16 pixel pictures are delineated at occipital bone image.SPECT bundled software can calculate swollen
Tumor and occipital bone region of interest99mTc-3P-RGD2 averagely absorbs intensity.Calculating tumour region of interest averagely absorbs intensity and (is defined as
T) and occipital bone region of interest averagely absorbs intensity (being defined as O) ratio, is defined as T/O.T/O=2.51 is calculated in this example
(T/O)/V ratio is calculated, if ratio is greater than 0.005, then it is assumed that shift risk higher than average value；If ratio is situated between
Between 0-0.005, then it is assumed that shift risk not higher than average value.(T/O)/V=0.0023 is calculated in this example, is less than
0.005.Follow-up is good to 20 months Partial controlls.
Embodiment 2:99mTc-3P-RGD2 imaging is used for mela-noma of choroid with ultrasonoscopy,
Patients surgery treat move ahead ultrasonoscopy with99mTc-3P-RGD2 imaging.
Ultrasonoscopy: eye ultrasonoscopy measures mela-noma of choroid base length and tumour height, according to following public affairs
Formula calculates volume: V=2 л a2B/3 (v: volume；A: tumour base length/2；B: height), according to this example substrate 9.5mm, height
3.2mm, volume 151.1mm3
99mTc-3P-RGD2 imaging: will99mTc-3P-RGD2 is injected intravenously according to 0.3mCi/Kg weight into patient's body, and 1
SPECT is imaged after hour, delineates region of interest, tumour region of interest delineates mode are as follows: delineates the side for being deeper than the color of background
Edge, occipital bone region of interest delineate mode are as follows: 16 pixel pictures are delineated at occipital bone image.SPECT bundled software can calculate swollen
Tumor and occipital bone region of interest99mTc-3P-RGD2 averagely absorbs intensity.Calculating tumour region of interest averagely absorbs intensity and (is defined as
T) and occipital bone region of interest averagely absorbs intensity (being defined as O) ratio, is defined as T/O.T/O=1.34 is calculated in this example
(T/O)/V ratio is calculated, if ratio is greater than 0.005, then it is assumed that shift risk higher than average value；If ratio is situated between
Between 0-0.005, then it is assumed that shift risk not higher than average value.(T/O)/V=0.0089 is calculated in this example, is greater than
0.005.Radioactive particle application therapy found hepatic metastases after 6 months.
Claims (2)
1.99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer, it is characterised in that:99mTc-3P-
RGD2 mediates SPECT imaging to be combined with ultrasound.
2. the new application of drug as described in claim 1, its implementation are as follows: before operative treatment99mTc-3P-RGD2 is mediated
SPECT detection is combined with ultrasound；SPECT delineates affected area, healthy opposite side, occipital bone region of interest, calculates and averagely absorbs concentration numbers
Value, calculating tumour averagely absorbs concentration and occipital bone region of interest averagely absorbs concentration values, is defined as T/O；Ultrasonoscopy measurement
Tumour longest edge and most broadside calculate gross tumor volume, are defined as V；(T/O)/V ratio is calculated, if (T/O)/V ratio is greater than
0.005, then it is assumed that shift risk larger；If if (T/O)/V ratio is between 0 to 0.005, then it is assumed that shift risk not
Higher than average level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710470269.XA CN109091682A (en) | 2017-06-20 | 2017-06-20 | 99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710470269.XA CN109091682A (en) | 2017-06-20 | 2017-06-20 | 99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109091682A true CN109091682A (en) | 2018-12-28 |
Family
ID=64795699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710470269.XA Pending CN109091682A (en) | 2017-06-20 | 2017-06-20 | 99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109091682A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2748528C1 (en) * | 2020-07-03 | 2021-05-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Method for detecting an inflammatory component that promotes tumor growth in initial choroidal melanoma |
| RU2790468C1 (en) * | 2022-05-04 | 2023-02-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Method for predicting the appearance of distant metastases of melanoma of the choroid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552949A (en) * | 2012-02-21 | 2012-07-11 | 安徽筑梦生物科技有限公司 | 99mTc-labeled RGD (Arginine-Glycine-Aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof |
| CN104667306A (en) * | 2015-02-09 | 2015-06-03 | 刘丽 | Chemical structure and preparation method of 99mTc-labeled RGD polypeptide trimer tumor imaging agent |
| CN106474495A (en) * | 2016-11-21 | 2017-03-08 | 中国医学科学院阜外医院 | Imido- oxalic acid99mRgd peptide diagnosing tumor medicine of Tc labelling and preparation method thereof |
-
2017
- 2017-06-20 CN CN201710470269.XA patent/CN109091682A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552949A (en) * | 2012-02-21 | 2012-07-11 | 安徽筑梦生物科技有限公司 | 99mTc-labeled RGD (Arginine-Glycine-Aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof |
| CN104667306A (en) * | 2015-02-09 | 2015-06-03 | 刘丽 | Chemical structure and preparation method of 99mTc-labeled RGD polypeptide trimer tumor imaging agent |
| CN106474495A (en) * | 2016-11-21 | 2017-03-08 | 中国医学科学院阜外医院 | Imido- oxalic acid99mRgd peptide diagnosing tumor medicine of Tc labelling and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| TONG FU等: "99mTc-3P-RGD2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin avb3-Targeted Therapy", 《CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS》 * |
| 桂新等: "脉络膜恶性黑色素瘤的超声显像", 《中国超声诊断杂志》 * |
| 闫冰等: "脉络膜黑色素瘤中整合素αvβ3 表达的研究", 《现代生物医学进展》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2748528C1 (en) * | 2020-07-03 | 2021-05-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Method for detecting an inflammatory component that promotes tumor growth in initial choroidal melanoma |
| RU2790468C1 (en) * | 2022-05-04 | 2023-02-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) | Method for predicting the appearance of distant metastases of melanoma of the choroid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miles et al. | Colour perfusion imaging: a new application of computed tomography | |
| Ghosh et al. | Monitoring early tumor response to vascular targeted therapy using super-resolution ultrasound imaging | |
| Stewart et al. | Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model | |
| US20160106870A1 (en) | Biocompatible fiducial marker using multi-block copolymers | |
| Badea et al. | Contrast enhanced ultrasonography (CEUS) in the characterization of tumor microcirculation. Validation of the procedure in the animal experimental model. | |
| Lonser et al. | Direct convective delivery of macromolecules to peripheral nerves | |
| Bruehlmeier et al. | Measurement of tumor hypoxia in spontaneous canine sarcomas | |
| CN109091682A (en) | 99mNew application of the Tc-3P-RGD2 in terms of predicting mela-noma of choroid transfer | |
| Gaustad et al. | Vascularization, oxygenation, and the effect of Sunitinib treatment in pancreatic ductal adenocarcinoma Xenografts | |
| Brooks et al. | Biophysical characterization of the leukemic bone marrow vasculature reveals benefits of neoadjuvant low-dose radiation therapy | |
| Veeravagu et al. | Volumetric analysis of intracranial arteriovenous malformations contoured for CyberKnife radiosurgery with 3-dimensional rotational angiography vs computed tomography/magnetic resonance imaging | |
| Santos et al. | Morphology, volume, and density characteristics of the parotid glands before and after chemoradiation therapy in patients with head and neck tumors | |
| Cherkashin et al. | Femoral access for central venous port system implantation | |
| Prakash | Nuclear Medicine: A Guide for Healthcare Professionals and Patients | |
| Thompson et al. | Quantitative dual-energy CT image guidance for thermochemical ablation: in vivo results in the rabbit VX2 model | |
| Aa et al. | Evaluation of absorbed dose distribution in melanoma B16F10 during contrast enhanced radiotherapy with intratumoral administration of dose-enhancing agent | |
| Chen et al. | Characterization of tumor vasculature derived from angiogenesis and vasculogenesis by high-frequency three-dimensional Doppler ultrasound | |
| Blohm et al. | Clinical utility, dose determination, and safety of ocular contrast‐enhanced ultrasonography in horses: A pilot study | |
| RU2369319C1 (en) | Method of projection representation of small parasagittal brain meningioms | |
| Ge et al. | Contrast‑enhanced ultrasound analysis of tissue perfusion in tumor-bearing mice following treatment with endostatin combined with radiotherapy | |
| Kim et al. | Feasibility of using volumetric contrast-enhanced ultrasound with a 3-D transducer to evaluate therapeutic response after targeted therapy in rabbit hepatic VX2 carcinoma | |
| Smith et al. | Clinical positioning accuracy for multisession stereotactic radiotherapy with the Gamma Knife Perfexion | |
| Green et al. | Total brain therapy: Technical considerations | |
| Rodrigues et al. | 99Tcm-HMPAO brain SPECT in the evaluation of prognosis after surgical resection of astrocytoma. Comparison with other noninvasive imaging techniques (CT, MRI and 201T1 SPECT) | |
| Daoud et al. | Primary hydatid cyst of the kidney revealed by hydatiduria: A case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181228 |
|
| WD01 | Invention patent application deemed withdrawn after publication |